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AbstRACt Rosacea is a common, chronic cutaneous disorder 
with a prevalence of 0.5-10%, predominantly affecting women. 
The disease presents with a heterogeneous clinical picture char-
acterized by transient flushing, persistent facial redness, telangi-
ectasias, and, in more severe clinical forms, the presence of in-
flammatory papules and pustules in the central third of the face. 
Although its pathophysiology is complex and still remains un-
known, factors that exacerbate the disease are well defined. They 
include genetic predisposition as well as external factors such as 
exposure to UV light, high temperature, and diet. Besides these 
well-known factors, recent studies suggest that drugs and vita-
mins could also be possible factors inducing rosacea-like derma-
titis or aggravating pre-existing rosacea. Although these are less 
common possible triggering factors, the aim of this article is to 
present the current knowledge on the association between use 
of certain drugs or vitamins and rosacea.
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INtRoDUCtIoN
Rosacea is a chronic skin inflammatory condition 
affecting the blood vessels and pilosebaceous units. 
Although it has many different clinical presentations, 
in the majority of cases it presents with centrofacial 
erythema and the presence of telangiectasia, occur-
ring more frequently in persons with fair complexion 
and light eyes (1). Although numerous studies have 
identified possible risk and triggering factors that in-
duce or exacerbate rosacea, the pathophysiology of 
rosacea still remains unknown (2). The contributing 
factors include family history of the disease, very light 
skin phototype, exposure to sun and high tempera-
ture, and diet (3,4). Apart from well identified possible 
contributing factors for rosacea, recent studies show 
emerging evidence that some drugs and vitamins 
aggravate rosacea or induce rosacea-like symptoms. 
These agents include topical corticosteroids, topi-
cal immunomodulators, oral parabens, epidermal 
growth factor receptor inhibitors (erlotinib, geftinib, 
cetuximab), calcium channel blockers, selective phos-
phodiesterase inhibitors, and vitamin B complex (5-9). 
Although the exact mechanism of how each of these 
agents contributes to the development of rosacea is 
not yet fully understood, some studies suggest that 
drug induced rosacea-like dermatitis occurs primarily 
in genetically predisposed individuals (6,10).
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toPICAL CoRtICosteRoIDs
The regular and excessive use of topical cortico-
steroids is identified as a potential risk factor that can 
aggravate or induce rosacea (11-13). Patients usually 
start using this topical therapy for the treatment of 
common dermatoses such as seborrheic dermatitis, 
acne, or melasma, usually as a result of recommen-
dations from nonmedical personnel or through self-
prescribing (12). Young women are the most affected 
population by this problem (12). After diminishing 
signs of the primary dermatitis due to the vasocon-
strictive and anti-inflammatory effects of the steroids, 
persistent use of these agents leads to epidermal at-
rophy, degeneration of dermal structure, and deterio-
ration of collagen, consequently leading to the skin 
disorder resembling rosacea (11,12,14). Skin atrophy 
can be observed on the centrofacial area, together 
with erythema, telangiectasia and possible papulo-
pustular eruptions, photosensitivity, and vulnerabil-
ity to bacterial, viral, and fungal infections (11,13,15). 
Furthermore, the immunosuppressive effects of 
corticosteroids facilitate an overgrowth of bacteria, 
which may act as superantigens, inducing formation 
of follicular granulomatous lesions (16). This relatively 
new dermatosis was given various names by different 
authors, such as perioral dermatitis, rosacea-like der-
matitis, steroid rosacea, steroid dermatitis resembling 
rosacea, and steroid-induced rosacea-like dermatitis 
(13-15,17). Pathological mechanisms that are thought 
to be responsible for development of rosacea-like 
symptoms include dilatation of blood vessels, release 
of proinflammatory cytokines, and accumulation of 
nitric oxide (12,18). Although some researchers sug-
gest that the minimum duration needed to develop 
rosacea-like symptoms was 3 months of continuous 
use, the average duration of persistent use of topical 
corticosteroids required to produce these adverse ef-
fects is in most cases 6 months or more (11,12). This 
variability is largely conditioned by individual genetic 
predisposition as well as the potency of the local cor-
ticosteroid used (11,13,15). Consequently, high-po-
tency topical corticosteroids such as clobetasol pro-
pionate, betamethasone, fluticasone, and mometa-
sone are more likely to induce this condition (11).
toPICAL IMMUNoMoDULAtoRs
Local immunomodulator therapy is used for vari-
ous skin diseases including atopic dermatitis, sebor-
rheic dermatitis, asteatotic eczema, contact dermati-
tis, or psoriasis localized in sensitive areas such as the 
face (19-22). Although these agents have a good safe-
ty profile and adverse effects are generally rare, there 
have been case reports of rosacea-like dermatitis, 
rosacea-like demodicosis, and granulomatous erup-
tions associated with topical use of immunomodula-
tors (16,19-21,23). Possible pathological mechanism 
responsible for the immunomodulator-induced ro-
sacea-like dermatitis could include different factors, 
such as vasoactive properties of topical immuno-
modulator therapy, proliferation of Demodex follicu-
lorum due to local immunosuppression, and an oc-
clusive effect which is more pronounced with use of 
tacrolimus ointment than with pimecrolimus cream 
(16,20-23). Although clinical presentation is similar to 
rosacea caused by topical corticosteroids, it is impor-
tant to emphasize the absence of skin atrophy during 
persistent use of topical immunomodulator therapy, 
unlike under corticosteroid therapy (16,24).
VItAMIN b
As far as vitamin B inducing rosacea is concerned, 
few studies have been conducted so far (10,25,26). Vi-
tamin B3 (niacin) has been associated with skin flush-
ing, while vitamins B2 (riboflavin), B6 (pyridoxine), 
and B12 (cyanocobalamin) have shown association 
with outbreak of acneiform lesions (5,10,25-29). There 
have also been reports of rosacea fulminans follow-
ing the administration of vitamin B derivatives; how-
ever, the reactions were associated with daily intake 
of vitamin B6 that exceeded the recommended daily 
allowance (5,10). Regarding treatment modalities for 
vitamin B--triggered rosacea, clinical symptoms tend 
to improve rapidly after discontinuation of the agent, 
while other standard therapy for rosacea does not 
achieve optimal therapeutic response (10,27). This 
type of cutaneous side effect of vitamin B appears 
to be more common in women than in men (10). Al-
though the pathological mechanism of vitamin B in 
development of rosacea-like dermatitis is not yet fully 
understood, the potential factor could be an irritation 
of the follicular epithelium, leading subsequently to 
an inflammatory reaction (5,10). In conclusion, vita-
min B-triggered rosacea-like dermatitis is rare and 
usually associated with the intake of large doses of 
vitamins over a shorter period of time, with early pre-
sentation of clinical symptoms.
VAsoACtIVe DRUGs
Vasoactive drugs, primarily vasodilators, could 
be possible triggers that can induce or exacerbate 
rosacea (30,31). Among this group of drugs, calcium 
channel blockers are most often associated with skin 
disorders, affecting dominantly the facial area. These 
agents are powerful peripheral arterial vasodilators 
and are frequently used in the treatment of ischemic 
heart disease or arterial hypertension (32). Although 
calcium channel blockers are in general rarely associ-
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ated with adverse skin reactions, flushing is a com-
mon adverse effect of these drugs experienced by 
5% of patients, with greater incidence in women than 
in men (30,33). Side effects such as the appearance 
of subclinical rosacea as well as the exacerbation 
of pre-existing rosacea have been described much 
more rarely (30,34,35). Spoendlin et al. observed the 
association between use of calcium channel blockers, 
beta-blockers, and other antihypertensive drugs and 
incidence of rosacea (36). Their results confirmed the 
hypothesis that calcium channel blockers increase the 
risk of rosacea, whereas beta-blocker use is associated 
with a slightly decreased risk of rosacea (36,37). Con-
sidering that in all current clinical guidelines for the 
treatment of essential hypertension calcium channel 
blockers belong to the first line therapy and rosacea 
is one of the most common skin disorders seen in dai-
ly practice, this possible association should be addi-
tionally evaluated (30). Furthermore, when possible, 
in cases of pronounced clinical symptoms choosing 
another first-line antihypertensive drug instead of 
calcium channel blockers should be recommended 
(30). Additionally, a few reports have suggested an as-
sociation between the use of calcium channel block-
ers and photosensitive reactions with telangiectasia 
appearing on the face (33,38-42). Although the un-
derlying pathological mechanism of calcium channel 
blockers in provoking telangiectasia could be in the 
vasodilatory action of these drugs, it is not clearly un-
derstood how they may cause photosensitivity (32). 
Another vasoactive group of drugs associated with 
rosacea-like symptoms are selective phosphodiester-
ase (PDE) inhibitors. These agents have been success-
fully introduced in the oral treatment of erectile dys-
function (6,43,44). Although these drugs are rarely as-
sociated with development of cutaneous side effects, 
rosacea-like symptoms were described in a few case 
reports (6). 
ePIDeRMAL GRowtH FACtoR ReCePtoR 
INHIbItoRs
Epidermal growth factor receptor inhibitors (EG-
FRI), including monoclonal antibodies (cetuximab 
and panitumumab) and the EGFR tyrosine kinase 
inhibitors (gefitinib, erlotinib, and lapatinib), are 
amongst the most extensively used targeted agents 
in the treatment of the most common solid tumors. 
These agents avoid many of the classic side effects 
associated with cytotoxic chemotherapy, but their 
use is frequently associated with cutaneous adverse 
effects (8,45). The pathological mechanism that is re-
sponsible for these cutaneous adverse effects is the 
inhibition of EGFR in the skin, since EGFR is physiolog-
ically expressed in epithelial tissues and hair follicles 
(8,45,46). The earliest and most common skin side 
effect is an acneiform or papulopustular skin rash 
which is found in up to two thirds of patients receiv-
ing any of these agents (8,45-49). Clinical presenta-
tion is usually mild or moderate and dose dependent, 
developing within the first few weeks of treatment, 
predominantly in 2nd and 3rd week after initiation of 
therapy (48,50). Apart from these cutaneous side ef-
fects associated with EGFR inhibitors, less common 
ones have also been described, mimicking other der-
matological conditions such as rosacea, seborrheic 
dermatitis, or folliculitis (9,46,49,53). Some research-
ers even suggest that the term acneiform rash should 
be changed to ‘rosacea-like’ or ‘rosaceiform’ (7,54). 
These hypotheses are based on the results of research 
that has shown increased density of Demodex follicu-
lorum in the skin under EGFR inhibitors, although the 
role of this agent in dermatological conditions is still 
controversial (7). Additionally, satisfactory response 
of the skin lesions to topical treatment with metroni-
dazole is another factor contributing this theory (55). 
It should be emphasized that the term “acneiform” or 
“papulopustular” rash does not describe these cuta-
neous side effects sufficiently, mostly because these 
lesions appear to be pathologically and etiologically 
distinct from acne vulgaris (7,45,49). Furthermore, 
heterogeneity in the definitions of skin toxicity/side 
effects is a result of different grading and reporting in 
trials, which are conducted primarily by oncologists 
and not by dermatologists. Consequently, when a 
‘‘rash’’ or ‘‘acneiform rash’’ is reported, it may include 
a broad spectrum of different clinical presentations 
including: pustular rash, erythematous rash, rosacei-
form dermatitis, acneiform dermatitis, exfoliative der-
matitis, papular rash, pruritic rash, generalized rash, 
and maculo-papular rash (52,54). Therefore, many 
researches have emphasized the need for more ac-
curate classification of EGFR inhibitor-associated cu-
taneous side effects (7,52,54).
CoNCLUsIoN
Rosacea is commonly seen in daily dermatologi-
cal practice. Its etiopathology still remains unknown. 
In this review, we focused on possible triggers of ro-
sacea or rosacea-like dermatitis apart from those that 
have already been identified, such as exposure to sun-
light and high temperatures, diet, and stress. Recent 
studies have demonstrated the association between 
the use of certain drugs or vitamins and development 
of rosacea-like dermatitis or exacerbation of preexist-
ing rosacea. The mechanisms that are responsible for 
this effect can only be partially explained, but they 
mainly depend on the pathophysiologic mechanism 
of the drug or vitamin that is used. Since there is a 
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considerable number of potentially rosacea-inducing 
drugs that are used in frequent medical conditions 
such as hypertension and ischemic heart disease, sol-
id tumors, erectile dysfunction, and atopic dermatitis, 
we emphasize the need for awareness of the fact that 
these incriminating agents could be possible trigger-
ing factors. In these specific situations rosacea-like 
dermatitis can also affect treatment compliance, con-
sequently interfering with the therapeutic regimen. 
Furthermore, it can cause a significant psychological 
burden and have an impact on patient quality of life. 
Regarding treatment options for drug induced ro-
sacea-like dermatitis, the only treatment modality is 
prompt discontinuation of the drug or vitamin, or in 
the case of a chronic medical disorder which requires 
uninterrupted therapy, choosing a drug with same 
action mechanism but from another class. It can be 
concluded that, considering recent evidence and 
observations on the influence of drugs or vitamins 
on rosacea development or aggravation, further re-
search should be conducted to objectivize the role of 
these potential triggering factors.
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